Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.53 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.53 |
| ▸ | BCL2 | P10415 | 2/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 2/20 | 0.40 |
| ▸ | LDHB | P07195 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.38 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | EYA3 | Q99504 | 3/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6735552 | 0.89 | GABRA1 (0.46) | GABRA1GABRB1BCL2MCL1GAA | |
| SCHEMBL6730807 | 0.88 | GABRA1 (0.42) | GABRA1GABRB1BCL2MCL1GAA | |
| SCHEMBL6734499 | 0.88 | GABRA1 (0.42) | GABRA1GABRB1BCL2MCL1GAA | |
| SCHEMBL6731441 | 0.87 | GLRA1 (0.43) | GABRA1GABRB1GAAHTTLMNA | |
| SCHEMBL6731106 | 0.84 | GABRA1 (0.46) | GABRA1GABRB1BCL2MCL1GAA | |
| SCHEMBL6734693 | 0.83 | CYP2C9 (0.43) | LMNALDHALDHBCNR2GPR55 | |
| SCHEMBL6735279 | 0.78 | PTPN1 (0.52) | MCL1GLRA1 | |
| SCHEMBL6738738 | 0.77 | CYP2C19 (0.38) | LMNAGLRA1CYP2C19 | |
| SCHEMBL6735422 | 0.76 | CYP2C19 (0.36) | LMNAGLRA1CYP2C19CYP2C9ALOX5 | |
| SCHEMBL6736525 | 0.75 | CYP2C19 (0.46) | GAAHTTLMNACNR2GPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6683107-B2 | THERAPY OF METABOLISM DISORDERS | WYETH | 2004-01-27 | — | — | US | disclosed |
| US-20030073709-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2003-04-17 | — | — | US | disclosed |
| US-6451845-B1 | ANTIDIABETIC AGENTS | WYETH | 2002-09-17 | — | — | US | disclosed |
| US-20020035272-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-21 | — | — | US | disclosed |
| US-6248764-B1 | ANTIDIABETIC AGENT; HYPOGLYCEMIC AGENT | AMERICAN HOME PRODUCTS CORPORATION | 2001-06-19 | — | — | US | disclosed |
| US-6103708-A | USEFUL IN TREATING METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073709-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | GPR119, INSR, FFAR3 | GABRA1 549/4885GABRB1 174/4885BCL2 1402/4885 |
| US-20020035272-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | INSR, GPR119, FFAR3 | GABRA1 682/4885GABRB1 215/4885BCL2 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.